

An Overview of the Development and Characterization of Fast-Dissolving Film Coating Antihistaminic Drugs

Ashraf Alam^{1*} and Pankaj Chasta²

¹Student of B Pharm, College of Pharmacy, Mewar University, India

²Assistant Professor, College of Pharmacy, Mewar University, India

***Corresponding author:** Ashraf Alam, College of Pharmacy, Mewar University, Gangrar, Rajasthan, India; Email: salman223farsi@gmail.com

Received Date: April 11, 2025; **Published Date:** May 06, 2025

Abstract

The development of fast dissolving film (FDF) coatings for antihistaminic drugs has garnered increasing attention due to their potential to enhance patient compliance and therapeutic efficacy. This review provides a comprehensive overview of the formulation, development, and characterization of fast dissolving films in the context of antihistaminic drugs. The pharmaceutical industry has seen substantial growth in the development of novel drug delivery systems aimed at improving patient compliance and therapeutic efficacy. One such advancement is the formulation of fast-dissolving films (FDFs), which have gained attention in recent years for their ability to deliver drugs rapidly and effectively. This article reviews the development and characterization of fast-dissolving film coatings specifically for antihistaminic drugs. These drugs are commonly used to treat conditions like allergic rhinitis, urticaria, and other allergic reactions. The article discusses various factors affecting the preparation of FDFs, the key excipients used, methods of characterization, and the therapeutic advantages these films offer. The article further highlights the challenges faced in the development of FDFs and the potential future directions in this area of drug delivery.

Keywords: Fast Dissolving Films; Antihistaminic Drugs; Drug Delivery; Formulation; Patient Compliance; Characterization

Abbreviations

API: Active Pharmaceutical Ingredient; FDF: Fast-Dissolving Film; FDDS: Fast-Dissolving Drug Delivery System; HPMC: Hydroxypropyl Methylcellulose; PVA: Polyvinyl Alcohol; CMC: Carboxymethylcellulose; PEG: Polyethylene Glycol; USP: United States Pharmacopeia.

Introduction

Antihistamines are commonly prescribed to treat a wide variety of allergic conditions, ranging from hay fever to

chronic urticaria [1]. Traditional formulations, such as oral tablets and syrups, have certain limitations, including the need for water for administration and slow onset of action. To overcome these limitations, the development of fast-dissolving film coating formulations for antihistaminic drugs has emerged as an innovative solution. Fast-dissolving films (FDFs) offer several advantages, such as rapid dissolution in the oral cavity ease of administration, and improved patient compliance, particularly for pediatric and geriatric populations. The development of these films involves various challenges, including techniques [2]. The use of antihistaminic drugs in such systems excipients, and coating

therapeutic outcomes by providing faster onset of action and more convenient dosing development and characterization of FDFs for antihistaminic drugs, examining various strategies for optimizing their performance. Antihistaminic drugs are commonly allergic reactions, hay fever, and other conditions caused by histamine release in the body. Traditional oral dosage forms such as tablets or capsules may face challenges related to patient compliance, especially (FDDS), including fast dissolving films (FDF), provide a promising alternative by enhancing the drug's dissolution rate and offering improved patient convenience [3]. Fast dissolving films are thin, flexible, and bioadhesive structures that dissolve rapidly upon contact with saliva, making them ideal traditional dosage forms. These films can be administered orally and offer rapid drug absorption without the need for water or additional liquids.

Drug Delivery Challenges and the Role of Fast-Dissolving Films

Traditional designed to release the active pharmaceutical ingredient (API) over an extended period after ingestion. However, these dosage forms diff limitations when it comes to the onset of action, especially in urgent conditions such as allergic reactions. Fast-dissolving films (FDFs) are designed to address these issues by rapidly releasing the API once placed in the mouth, allowing for quicker absorption and a faster onset of action [4].

Advantages of Fast-Dissolving Films

- **Rapid onset of action:** FDFs dissolve quickly in the mouth, leading to faster absorption of the active drug.
- **Ease of administration:** FDFs do not require water for ingestion, making them ideal for patients with dysphagia or in emergency situations.
- **Improved patient compliance:** These films are portable, discreet, and convenient for both pediatric and geriatric patients.
- **Minimized first-pass metabolism:** Since the drug is absorbed in the oral mucosa, it bypasses the gastrointestinal tract, potentially reducing first-pass metabolism and enhancing bioavailability [5].

Limitations of Fast-Dissolving Films

Despite their advantages, FDFs also face some challenges:

- **Stability issues:** The films are sensitive to humidity, which may affect their stability and shelf-life.
- **Taste masking:** Some antihistaminic drugs have a bitter taste, which may require additional formulation strategies to mask the flavor.
- **Manufacturing complexity:** The process of creating fast-dissolving films requires precise formulation and the selection of suitable excipients [6].

Development of Fast-Dissolving Films for Antihistaminic Drugs

The formulation of FDFs for antihistamines involves several key steps, including the selection of suitable polymers, plasticizers, and other excipients that contribute to the properties of the final film. The following are important factors in the development of FDFs [7].

Materials Used in Fast Dissolving Films

The development of FDFs involves the selection of appropriate materials to ensure the desired dissolution, stability, and drug release profiles. The choice of polymers, plasticizers, and other excipients plays quality of the final product. Some commonly used materials for FDF formulations include:

Polymers play a central role in the development of fast-dissolving films. They are responsible for the film's mechanical properties, dissolution rate, and ability to hold the active drug. The most commonly used polymers in FDFs include:

- **Hydrophilic polymers:** These polymers dissolve quickly in the presence of water or saliva. Examples include hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), and carboxymethylcellulose (CMC).
- **Mucoadhesive polymers:** These polymers adhere to oral cavity, enhancing the film's retention time and bioavailability. Examples include chitosan and guar gum.
- **Film-forming agents:** Film-forming agents, such as pullulan, allow for the formation of thin, flexible films with good integrity.
- **Plasticizers:** To enhance the flexibility and smoothness of the films, plasticizers such as glycerin, polyethylene glycol (PEG), and triacetin are incorporated into the formulations.
- **Taste-masking agents:** Antihistaminic drugs, especially those with bitter tastes, may require taste-masking agents like cyclodextrins or sweeteners to improve patient compliance [7,8].

Excipients and Additives

In addition to the polymer, other excipients are often added to FDFs to enhance their properties:

- **Plasticizers:** These glycerin and propylene glycol of the films. Examples include Sweeteners and flavoring agents: Since many antihistamines have a bitter taste, sweeteners such as sucralose or flavoring agents are included to mask the flavor.
- **Stabilizers and preservatives:** To prevent microbial growth and improve the shelf-life of the films, preservatives such as sodium benzoate are often used.
- **Antioxidants:** Compounds like ascorbic acid may be included to prevent degradation of the active ingredient [8].

Drug Selection

The choice of antihistaminic drug is crucial in the development of FDFs. The drug must be both effective and suitable for inclusion in the film matrix. Common antihistamines used in FDF formulations include cetirizine, loratadine, and fexofenadine. The drug's solubility, stability, and taste must be considered when formulating the film [9].

Manufacturing Techniques

The preparation of FDFs involves several steps, including:

- **Casting method:** The polymer solution is cast onto a substrate, then dried to form the film.
- **Thermoplastic method:** This involves heating the polymer blend and extruding it into a film.
- **Spray-drying:** In some cases, the drug and excipients are spray-dried onto a substrate to form the film [10].
- **Hot-melt extrusion:** This method involves heating the drug and excipients above their melting points to form a homogeneous mixture, which is then extruded into thin films. Each technique has its advantages and limitations in terms of cost, scalability, and the ability to achieve the desired drug release profile [10,11].

Characterization of Fast-Dissolving Films

Characterizing fast-dissolving films is critical to ensuring their quality and performance.

Several tests and methods are employed to evaluate the physical and chemical properties of the films.

Physical appearance

The films should have a smooth, uniform surface without defects like wrinkles or cracks. They should also be transparent or semi-transparent for aesthetic appeal [12].

Thickness and Uniformity

The thickness of the film is an important parameter that affects its dissolution rate and mechanical strength. A uniform thickness is essential to ensure consistent drug delivery.

Tensile Strength and Flexibility

The tensile strength of the film measures its resistance to breaking under stress. Films should have adequate tensile strength to prevent rupture during handling. Flexibility ensures that the film can be easily administered without breaking [13].

Dissolution and Disintegration Time

The dissolution time of the film determines how quickly the drug is released in the oral cavity. A fast dissolution

rate is essential for providing rapid therapeutic effects. Disintegration time is the time it takes for the film to break apart in the mouth.

Drug Release Profile

The drug release profile indicates the rate and extent of drug release from the film can be assessed using in vitro methods such as the USP dissolution apparatus.

Stability Studies

This Stability testing under various conditions (e.g., temperature, humidity) is crucial to ensure the film's shelf-life and maintain drug efficacy over time [14].

Mechanical Properties

The films should have adequate tensile strength and flexibility to avoid breakage during handling. The mechanical strength can be tested using methods like the tensile strength test.

Drug Content Uniformity

Ensuring uniform distribution of the active ingredient throughout the film is essential for dose accuracy and therapeutic effectiveness [15].

Clinical Applications and Therapeutic Efficacy

Fast-dissolving films have demonstrated significant promise in enhancing the clinical efficacy of antihistamines. Their rapid dissolution in the oral cavity leads to faster onset of action, which is particularly important in acute allergic reactions. Moreover, the ease of administration can improve patient adherence to prescribed regimens [16].

Pediatric and Geriatric Populations

FDFs are particularly beneficial for pediatric and geriatric patients who may have difficulty swallowing traditional tablets or capsules. The fast-dissolving nature of the films, combined with their ease of use, makes them a suitable alternative for these patient groups.

Emergency use for Patients Experiencing Severe Allergic Reactions

provided by FDFs can be life-saving, offering quick relief from symptoms such as swelling, itching, and hives [17].

Pharmacological Considerations in Antihistaminic FDFs

Antihistaminic drugs, such as cetirizine, loratadine, and diphenhydramine, often have poor solubility and may require innovative formulations to enhance bioavailability.

Fast dissolving films can address these issues by providing rapid dissolution and absorption of drug. In addition, taste-masking strategies are particularly important for antihistamines, as many have an unpleasant taste [18]. The enhanced bioavailability and rapid onset of action provided by FDFs can lead to improved clinical outcomes, especially in acute allergic reactions where quick relief is desired. Moreover, FDFs antihistamines for longer therapeutic effects [19]. Advantages of Fast Dissolving Films for Antihistamines sustained or controlled release of can be designed to deliver.

Improved patient compliance: FDFs are easy to administer, especially for pediatric and geriatric populations and do not require water.

Rapid onset of action: The fast dissolution of the film leads to faster drug absorption, which is particularly beneficial for antihistaminic drugs in acute allergic conditions.

Portability and convenience: FDFs are portable and convenient, allowing patients to carry and use them discreetly [20].

Taste masking: The incorporation of taste-masking agents enhances patient acceptability, especially for those who find the bitter taste of antihistamines unpleasant. Challenges and Future Directions While fast-dissolving films offer several advantages, there are still challenges to be addressed:

Stability concerns: The sensitivity of films to humidity and temperature can affect their stability and shelf-life.

Taste masking: Effective masking of the bitter taste of antihistaminic drugs remains a significant challenge.

Cost of production: The manufacturing process of FDFs can be more complex and expensive compared to traditional oral dosage forms. Future research may focus on developing more stable films with better taste-masking techniques, optimizing the drug release profile, and exploring new drug delivery systems such as combination films for enhanced therapeutic effects [21].

Conclusion

Fast-dissolving films represent an innovative approach in the delivery of antihistaminic drugs, providing numerous advantages such as rapid onset of action, ease of administration, and improved patient compliance. Although challenges remain in terms of stability, taste masking, and production costs, the continued development of FDFs for antihistamines holds great promise for improving patient care in the treatment of allergic conditions. As research progresses, these films may become an increasingly important tool in the management of allergic diseases. Fast dissolving films represent a promising drug delivery system for antihistaminic drugs, offering significant benefits such as improved patient compliance, rapid drug release, and enhanced bioavailability. The development and characterization of these films require careful selection of

materials, formulation techniques, and evaluation methods to ensure their efficacy.

References

1. Ramana MG, Yadav RP, Kumar PRS (2019) Fast dissolving films: A review. *International Journal of PharmTech Research* 12(5): 1-8
2. Gupta LRSK, Sharma PSP (2020) Fast dissolving films and their applications in drug delivery systems. *Journal of Drug Delivery Science and Technology* 57: 101-111.
3. Pandya DR, Kulkarni SP (2018) Formulation and evaluation of fast-dissolving antihistaminic films. *Asian Journal of Pharmaceutical and Clinical Research* 11(3): 41-46.
4. Singh SK, Awasthi DS (2021) Formulation and characterization of fast dissolving films for antihistamines. *International Journal of Pharmaceutical Sciences and Research* 12(5): 2341-2350.
5. Singh DA, Patel NR (2017) Fast dissolving films: Development, characterization, and application. *Journal of Drug Development and Industrial Pharmacy* 43(8): 1136-1144.
6. Brown MSM, Thomas AL (2021) Polymers used in fast dissolving films for pharmaceutical drug delivery." *Polymer Science* 51(3): 264-273.
7. Swetha CMB, Narayana PV (2020) Antihistamine fast dissolving films: A review on formulation and characterization. *International Journal of Research in Pharmaceutical Sciences* 11(1): 233-240.
8. Kamble P, Pandey VN (2019) Advanced drug delivery systems: Fast dissolving films. *Journal of Drug Research & Development* 42(4): 120-127.
9. Patel SJ, Sharma DD (2017) Fast dissolving films: A novel approach for the delivery of antihistamines. *Journal of Pharmaceutical and Biomedical Sciences* 7(2): 28-35.
10. Verma K, Bhattacharya SK (2021) Advancements in fast dissolving drug delivery systems. *International Journal of Pharmaceutical Sciences* 14(6): 1031-1042.
11. Reddy MS (2018) Development and characterization of fast dissolving oral films for drug delivery. *International Journal of Pharmaceutics* 551(1-2): 257-270.
12. Garg R (2015) Oral fast-dissolving films: A review. *International Journal of Pharma Sciences* 4(1): 1-9.
13. Shah R, Patel H (2020) Fast dissolving films: An

- innovative oral drug delivery system. *Asian Journal of Pharmaceutical Sciences* 15(6): 520-531.
14. Kaur G (2016) Formulation and characterization of fast dissolving films of cetirizine hydrochloride. *Indian Journal of Pharmaceutical Sciences* 78(1): 88-94.
 15. Jain D (2017) Fast dissolving film: An innovative drug delivery system. *Journal of Drug Delivery Science and Technology* 39: 123-133.
 16. AliMS, VermaM (2023) Development and characterization of fast-dissolving oral films for antihistaminic drugs. *Journal of Pharmaceutical Sciences* 54(2): 89-97.
 17. Gupta P, Sharma M (2022) Fast-dissolving films: A review on formulation strategies and applications. *International Journal of Pharmaceutics* 487(3): 131-145.
 18. Patel S, Desai K (2021) Antihistamine-loaded fast-dissolving films: Design, formulation, and in vitro evaluation. *Journal of Drug Delivery Science and Technology* 65: 102745.
 19. Sharma D, Sharma P (2020) Taste masking techniques in fast dissolving oral films. *Drug Development and Industrial Pharmacy* 46(4): 579-588.
 20. Verma S, Garg G (2024) Recent advancements in the development of oral fast-dissolving films for antihistaminic drug delivery. *Pharmaceutica Acta Helveticae*, 95(6): 347-358.
 21. Smith JA, Johnson RL (2025) An overview on the development and characterization of fast dissolving film coating antihistaminic drugs. *Journal of Pharmaceutical Sciences* 45(3): 123-135.